TL

Tiffany Le

Principal at NEA (New Enterprise Associates)

San Francisco, California

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $2,000,000.00

  • Max Investment:

    $50,000,000.00

  • Target Investment:

    $25,000,000.00

Skills

Strategy
Mergers
Data Analysis
Financial Modeling
Financial Analysis

Education

Lists including Tiffany

AH
AE
AF
AJ

Based in SF

3078 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Amber Therapeutics

Series A

Total Funding: $100M

Work Experience

NE
New Enterprise Associates (NEA)

2020

  • Principal

    2020

    Invest across medtech, healthtech, and the intersection of technology and life sciences. Board Director: Allay Therapeutics, Amber Therapeutics, FIRE1/Norm Labs, Magenta Medical, Revelle Aesthetics, ExploraMed (incubator), X9 (stealth) Board Observer: Moximed, Setpoint Medical, Willow Past/Exited: Relievant (Medtronic Acq.), Eargo (Nasdaq: EAR), Vesper (Philips Acq.), Intact Vascular (Philips Acq.)

KP
Kaiser Permanente Ventures

2019 - 2020

  • Investor

    2019 - 2020

GE Ventures

2018 - 2018

  • Healthcare Investments, Summer MBA Intern

    2018 - 2018

A
Amgen

2017 - 2017

  • Drug Delivery, Design Thinking, & Patient Experience

    2017 - 2017

    Externship while at LEK

LC
L.E.K. Consulting

2012 - 2017

  • Senior Consultant, Life Sciences

    2015 - 2017

    Managed teams of Associates and Life Science Specialists in strategic projects (M&A, pipeline optimization, product launch, and international expansion) across pharma, medtech, diagnostics, and digital health. Particular focus on personalized medicine and novel therapeutics

  • Senior Associate Consultant, Life Sciences

    2014 - 2015

    Early promotion (2-year role)

  • Associate

    2012 - 2014

    Early promotion (2-year role)